期刊
BIOORGANIC & MEDICINAL CHEMISTRY
卷 28, 期 22, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2020.115773
关键词
Etoposide; Podophyllotoxin; Topoisomerase; Cancer; HCT-116; A549
资金
- American Foundation of Pharmaceutical Education (AFPE) -Gateway to Research Scholarship
- Lipscomb University College of Pharmacy
- Belmont University Biology Department
Etoposide is a widely-used anticancer agent that targets human type II topoisomerases. Evidence suggests that metabolism of etoposide in myeloid progenitor cells is associated with translocations involved in leukemia development. Previous studies suggest halogenation at the C-2 ' position of etoposide reduces metabolism. Halogens were introduced into the C-2 ' position by electrophilic aromatic halogenation onto etoposide (ETOP, 1), podophyllotoxin (PPT, 2), and 4-dimethylepipodophyllotoxin (DMEP, 3), and to bridge the gap of knowledge regarding the activity of these metabolically stable analogs. Five halogenated analogs (6-10) were synthesized. Analogs 8-10 displayed variable ability to inhibit DNA relaxation. Analog 9 was the only analog to show concentration-dependent enhancement of Top2-mediated DNA cleavage. Dose response assay results indicated that 8 and 10 were most effective at decreasing the viability of HCT-116 and A549 cancer cell lines in culture. Flow cytometry with 8 and 10 in HCT-116 cells provide evidence of sub-G1 cell populations indicative of apoptosis. Taken together, these results indicate C-2 ' halogenation of etoposide and its precursors, although metabolically stable, decreases overall activity relative to etoposide.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据